Alphamab Oncology has submitted the IND application for JSKN016, an anti-HER3xTROP2 ADC designed for the treatment of solid tumors in China.
JSKN016 represents a potential first-in-class bispecific ADC, developed using the glycan-specific conjugation platform to target both HER3 and TROP2. No further details have been reported, and we will provide updates as they become available.
Anti-TROP2 ADC, sacituzumab govitecan, has received approval for the treatment of breast cancer and urothelial cancer. Lung cancer may be the next targeting indication.
Concurrently, anti-HER3 ADCs are widely investigated for their therapeutic potential in both lung cancer and breast cancer.
Comments